Completed PHASE4 INTERVENTIONAL NCT00170378

The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

Sponsor: Aventis Pharmaceuticals

Conditions Brain Injury Venous Thrombosis

Interventions Enoxaparin

Updated 8 times since 2017 Last updated: Jun 26, 2017 Started: Dec 31, 2002 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00170378, this PHASE4 trial focuses on Brain Injury and Venous Thrombosis and remains completed. Sponsored by Aventis Pharmaceuticals, it has been updated 8 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Apr 2020 — Jan 2021 [monthly]

Completed PHASE4
May 2019 — Apr 2020 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — May 2019 [monthly]

Completed PHASE4
Jul 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Suspended → Completed
Jan 2017 — Jul 2017 [monthly]

Suspended PHASE4

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aventis Pharmaceuticals
Hennepin Healthcare Research Institute

Data source: Hennepin Healthcare Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States